• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity! Product Image

VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!

  • ID: 1948434
  • October 2011
  • MP Advisors

Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. We expect most of the near term milestones related to Earnings, Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. For more details, please read our report released on 25th October, 2011 on VRTX titled “HCV/HIV Co-Infection – An Untapped Opportunity!”

Note: Product cover images may vary from those shown

- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis

Note: Product cover images may vary from those shown

- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos